One-Stop manaGemEnT For A Swift Initiation of Endovascular Therapy - An International, Multicenter, Pragmatic Randomized Controlled Trial
Launched by PROF. DR. JAN LIMAN · Jun 26, 2025
Trial Information
Current as of July 13, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a faster way to treat certain types of stroke caused by a blockage in a large or medium blood vessel in the brain. Normally, when someone arrives at the hospital with a stroke, they first get a brain scan in one room, and if a blockage is found, they are moved to another room for a procedure called endovascular therapy (EVT) to remove the clot. This trial is testing a “One-Stop” approach where both the brain scan and the treatment happen in the same room, which could save important time and improve recovery.
The trial is open to adults who have sudden, severe stroke symptoms suggesting a blockage in a large or medium blood vessel, and who arrive at the hospital within 4.5 hours of their symptoms starting. Participants need to have been independent before the stroke and able to give consent. During the study, patients will be randomly assigned either to the usual two-room process or the One-Stop approach, but everyone will receive the best care based on current medical guidelines. The researchers want to see if the One-Stop method leads to better recovery and less long-term disability. If successful, this new way of treating stroke could help more patients live independently and reduce healthcare costs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symptoms suggestive of an acute ischemic stroke caused by a large or medium vessel occlusion as defined by a National Institute of Health Stroke Scale (NIHSS) Score of ≥ 10 points
- • Patient presents directly to the treating hospital (mothership patient) within 4.5 hours of last seen well (LSW)
- • Age ≥ 18 years
- • Patient was independent in daily activities prior to the stroke (pre stroke modified Rankin Scale of 0 - 2)
- • Endovascular treatment team available (Neurologist, Interventionist, Anesthesiologist, Nursery, Technicians)
- • Informed Consent as documented by signature or fulfilling the criteria for emergency consent procedures
- Exclusion Criteria:
- • Severe comorbidities, which will likely prevent improvement or follow-up
- • In-hospital stroke
- • Clinical symptoms suggestive of intracranial hemorrhage (deterioration of patient during transport, vomiting or depressed consciousness)
- • Strong suspicion of functional neurological symptom disorder / conversion disorder
- • Hemodynamically unstable patients who require advanced vital support
- • Angiography room occupied by other procedure
About Prof. Dr. Jan Liman
Prof. Dr. Jan Liman is a distinguished clinical researcher specializing in neurology, with extensive expertise in designing and conducting advanced clinical trials. Renowned for his commitment to advancing medical knowledge and patient care, he leads innovative studies aimed at improving diagnostic and therapeutic strategies. His work is characterized by rigorous methodology and a patient-centered approach, contributing significantly to evidence-based medicine in his field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nürnberg, , Germany
Basel, , Switzerland
Patients applied
Trial Officials
Jan Liman, Dr
Principal Investigator
Klinkum Nürnberg
Marios Psychogios, Dr.
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported